Delivery System and Nanozyme: Nanotechnology‐Based Natural Sources Promise New Approaches in Colorectal Cancer Management
Source abstract
Abstract
ABSTRACT The worldwide prevalence of colorectal cancer (CRC) makes it a leading cause of death among malignancies. The development of CRC depends on multiple factors, including genetic inheritance, environmental contact, personal habits and modifications in the gut microbiota. The current diagnostic methods primarily include colonoscopy and advanced imaging, which guide treatment based on cancer stage and spread. The standard treatment methods, including chemotherapy, targeted biologics and surgical resection, face multiple challenges that limit their effectiveness because of systemic toxicity, acquired resistance and the inability to target tumour‐specific pathways. The shortcomings of traditional therapeutic approaches have led to increased scientific interest in integrative methods that can support or enhance established strategies. Nanotechnology plays a promising role in the treatment of CRC by enabling targeted delivery systems directly to tumour cells, which reduces side effects and improves treatment effectiveness. The review focuses on how nanotechnology‐based biocompatible nanoparticles (NPs) function to improve drug and herb pharmacokinetics and deliver to tumours while minimising adverse effects.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Nursing College of Applied Medical Sciences King Faisal University Al‐Ahsa Saudi Arabia
Faculty of Medicine Galala University New Galala City, Suez Egypt
Department of Public Health, College of Applied Medical Sciences King Faisal University Al‐Ahsa Saudi Arabia
Department of Basic Medical Sciences, Health Sector Galala University New Galala City, Suez Egypt
References (100+)
Show source-provided references
1. 10.1177/1073274821105669210.1177/10732748211056692 ↗
2. Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‐Up10.1016/j.annonc.2020.06.022 ↗
3. 10.1053/j.gastro.2019.07.05510.1053/j.gastro.2019.07.055 ↗
4. 10.1016/j.cbi.2022.11017010.1016/j.cbi.2022.110170 ↗
5. 10.1177/205064061988804010.1177/2050640619888040 ↗
6. 10.1038/nrdp.2015.6510.1038/nrdp.2015.65 ↗
7. 10.1016/j.ctrv.2015.06.00710.1016/j.ctrv.2015.06.007 ↗
8. 10.3390/cancers1421520310.3390/cancers14215203 ↗
9. 10.3748/wjg.v21.i43.1223410.3748/wjg.v21.i43.12234 ↗
10. 10.3748/wjg.15.359710.3748/wjg.15.3597 ↗
11. 10.1053/j.gastro.2008.02.09810.1053/j.gastro.2008.02.098 ↗
12. 10.1016/j.apsb.2019.08.00310.1016/j.apsb.2019.08.003 ↗
13. Nanozymes in Tumor Theranostics10.3389/fonc.2021.666017 ↗
14. 10.3390/ijms2302072410.3390/ijms23020724 ↗
15. 10.3390/cancers1304059410.3390/cancers13040594 ↗
16. 10.1097/00005344‐200605001‐0001410.1097/00005344‐200605001‐00014 ↗
17. 10.3390/pharmaceutics1302025110.3390/pharmaceutics13020251 ↗
18. Immunomodulatory and Anti‐Inflammatory Therapeutic Potential of Gingerols and Their Nanoformulations10.3389/fphar.2022.902551 ↗
19. 10.2165/00002018‐200528050‐0000510.2165/00002018‐200528050‐00005 ↗
20. 10.4143/crt.2004.36.4.23510.4143/crt.2004.36.4.235 ↗
21. 10.1159/00008848010.1159/000088480 ↗
22. 10.1056/NEJMoa140310810.1056/NEJMoa1403108 ↗
23. 10.1097/MD.000000000000633510.1097/MD.0000000000006335 ↗
24. 10.1080/14737140.2022.214751210.1080/14737140.2022.2147512 ↗
25. 10.1016/S1470‐2045(22)00197‐810.1016/S1470‐2045(22)00197‐8 ↗
26. 10.1016/S1470‐2045(24)00380‐210.1016/S1470‐2045(24)00380‐2 ↗
27. 10.1016/j.esmoop.2022.10063310.1016/j.esmoop.2022.100633 ↗
28. 10.3390/cancers1513346510.3390/cancers15133465 ↗
29. 10.1007/s40265‐018‐0938‐y10.1007/s40265‐018‐0938‐y ↗
30. 10.2147/OTT.S15676010.2147/OTT.S156760 ↗
31. 10.7150/jca.8771910.7150/jca.87719 ↗
32. Complementary and Alternative Medicine Use Among Colorectal Cancer Patients in Alberta, Canada
33. 10.1016/j.ctim.2012.02.00410.1016/j.ctim.2012.02.004 ↗
34. 10.21608/ejchem.2023.203996.782210.21608/ejchem.2023.203996.7822 ↗
35. 10.1097/MD.000000000000279310.1097/MD.0000000000002793 ↗
36. 10.1016/j.nut.2018.02.00210.1016/j.nut.2018.02.002 ↗
37. 10.1007/s00432‐004‐0642‐z10.1007/s00432‐004‐0642‐z ↗
38. Alamgir A. N. M. · 2018 · 58510.1007/978-3-319-92387-1_7 ↗
39. 10.1098/rsob.22035510.1098/rsob.220355 ↗
40. 10.1038/sj.bjc.660161910.1038/sj.bjc.6601619 ↗
41. 10.1186/1471‐230X‐10‐9610.1186/1471‐230X‐10‐96 ↗
42. 10.3389/fmicb.2022.101033210.3389/fmicb.2022.1010332 ↗
43. 10.1016/j.bbadis.2014.10.00610.1016/j.bbadis.2014.10.006 ↗
44. 10.3109/07357907.2010.55059210.3109/07357907.2010.550592 ↗
45. 10.1016/j.ejca.2009.04.02610.1016/j.ejca.2009.04.026 ↗
46. 10.1021/acs.nanolett.2c0016710.1021/acs.nanolett.2c00167 ↗
47. 10.3390/medicina5708075710.3390/medicina57080757 ↗
48. 10.1111/luts.1246210.1111/luts.12462 ↗
49. 10.1016/j.radonc.2019.07.02410.1016/j.radonc.2019.07.024 ↗
50. 10.4239/wjd.v12.i7.102610.4239/wjd.v12.i7.1026 ↗
51. 10.3390/pathogens1004045810.3390/pathogens10040458 ↗
52. 10.1039/D0RA05279E10.1039/D0RA05279E ↗
53. 10.7150/ijms.2263110.7150/ijms.22631 ↗
54. 10.1016/j.vetpar.2011.05.02810.1016/j.vetpar.2011.05.028 ↗
55. 10.1038/sj.bjp.070713010.1038/sj.bjp.0707130 ↗
56. 10.3389/fonc.2023.121160310.3389/fonc.2023.1211603 ↗
57. 10.3390/polym1507159610.3390/polym15071596 ↗
58. 10.1016/j.jsps.2014.11.01010.1016/j.jsps.2014.11.010 ↗
59. 10.1016/j.ejps.2023.10647710.1016/j.ejps.2023.106477 ↗
60. 10.7150/thno.4541310.7150/thno.45413 ↗
61. Synthesis of Silver Nanoparticles: Chemical, Physical and Biological Methods
62. 10.3390/ijms2311598210.3390/ijms23115982 ↗
63. 10.1007/s43994‐024‐00165‐710.1007/s43994‐024‐00165‐7 ↗
64. 10.3390/nano1213214410.3390/nano12132144 ↗
65. 10.3390/antibiotics703006710.3390/antibiotics7030067 ↗
66. 10.1016/j.sjbs.2020.09.02110.1016/j.sjbs.2020.09.021 ↗
67. 10.3390/biom1201003110.3390/biom12010031 ↗
68. 10.1016/j.biopha.2022.11295110.1016/j.biopha.2022.112951 ↗
69. 10.1186/s12935‐023‐03115‐110.1186/s12935‐023‐03115‐1 ↗
70. What We Need to Know About Liposomes as Drug Nanocarriers: An Updated Review
71. 10.3748/wjg.v28.i25.286710.3748/wjg.v28.i25.2867 ↗
72. 10.1016/j.eurpolymj.2023.11187710.1016/j.eurpolymj.2023.111877 ↗
73. pH‐Responsive Polymer Nanomaterials for Tumor Therapy10.3389/fonc.2022.855019 ↗
74. 10.3390/nano1007140310.3390/nano10071403 ↗
75. 10.1016/j.jconrel.2015.10.00610.1016/j.jconrel.2015.10.006 ↗
76. 10.1016/j.jconrel.2016.01.03410.1016/j.jconrel.2016.01.034 ↗
77. 10.1016/j.scenv.2025.10023810.1016/j.scenv.2025.100238 ↗
78. 10.1016/j.bcab.2023.10278810.1016/j.bcab.2023.102788 ↗
79. Advances of Green Synthesized Nanomaterials in Different Industries
80. 10.1039/D4RA06340F10.1039/D4RA06340F ↗
81. 10.1039/D1RA08374K10.1039/D1RA08374K ↗
82. 10.1080/21691401.2020.181431310.1080/21691401.2020.1814313 ↗
83. Green Synthesized Silver Nanoparticles Using the Plant‐Based Reducing Agent Matricaria chamomilla Induce Cell Death in Colorectal Cancer Cells
84. 10.3390/nano1523176710.3390/nano15231767 ↗
85. 10.3390/ph1504045510.3390/ph15040455 ↗
86. MicroRNA381 Protects Myocardial Cell Function in Children and Mice With Viral Myocarditis Via Targeting Cyclooxygenase2 Expression
87. 10.1186/s11671‐024‐04152‐z10.1186/s11671‐024‐04152‐z ↗
88. 10.3390/medicina5709086910.3390/medicina57090869 ↗
89. 10.1021/acsomega.3c0393310.1021/acsomega.3c03933 ↗
90. 10.1021/acsanm.4c0429410.1021/acsanm.4c04294 ↗
91. 10.1016/j.mtbio.2023.10080910.1016/j.mtbio.2023.100809 ↗
92. 10.1186/s12944‐024‐02301‐y10.1186/s12944‐024‐02301‐y ↗
93. 10.1016/j.ijpharm.2023.12358310.1016/j.ijpharm.2023.123583 ↗
94. 10.1016/j.phymed.2021.15389010.1016/j.phymed.2021.153890 ↗
95. 10.2147/IJN.S23277710.2147/IJN.S232777 ↗
96. 10.1631/jzus.B082023810.1631/jzus.B0820238 ↗
97. 10.3390/ijms2010245410.3390/ijms20102454 ↗
98. 10.1038/sj.onc.120298010.1038/sj.onc.1202980 ↗
99. 10.1002/ijc.2459310.1002/ijc.24593 ↗
100. 10.3892/ol.2021.1244710.3892/ol.2021.12447 ↗